ReviewAnnals of pediatric cardiology
Emerging therapeutic strategies for the failing Fontan circulation.
Review in Annals of pediatric cardiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Fontan circulation: Beyond hemodynamics to a unified disease paradigm.Annals of pediatric cardiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with Fontan circulation face progressive multisystem dysfunction driven by venous hypertension, lymphatic failure, and metabolic derangements. This state-of-the-art review synthesizes evidence across hemodynamic, lymphatic, pulmonary vascular, and metabolic domains to outline emerging therapies and a pragmatic care framework. We summarize data on exercise rehabilitation; pulmonary vasodilators; lymphatic imaging-guided interventions; metabolic modulation including bile acid sequestration and SGLT2 inhibition; arrhythmia prevention; mechanical circulatory support; and transplantation, including combined heart-liver strategies. Recognizing limitations of conventional randomized trials in this heterogeneous, small population, we propose adaptive, registry-embedded, and platform designs with harmonized phenotypes and core outcomes. This review aims to bridge mechanistic insight and clinical application, offering clinicians a concise roadmap and researchers a set of testable hypotheses to improve survival, function, and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.